This inventor holds 2 USPTO granted patents and 8 published patent applications. Top assignee: Glaxosmithkline LLC. Active years: 2024-2026.
Company Filing History:
Years Active: 2024-2026
Title: Barbara Jane Klencke: Innovator in Myelofibrosis Treatment
Introduction
Barbara Jane Klencke is a notable inventor based in Plymouth, MI (US). She has made significant contributions to the field of medicine, particularly in the treatment of myelofibrosis. With a total of 2 patents, her work has the potential to improve the lives of many patients suffering from this condition.
Latest Patents
Klencke's latest patents focus on platelet count-agnostic methods of treating myelofibrosis. A reanalysis of the SIMPLIFY 1 and 2 trials data indicates that momelotinib (MMB) is effective in JAKi-naïve patients and in second-line therapy to RUX. This treatment provides benefits such as reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patients at risk for thrombocytopenia from the underlying disease and RUX therapy. The methods described include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to subjects identified as having myelofibrosis and a platelet count of less than 150×10/L. Additionally, methods are outlined for administering a stable dose of momelotinib over a period of weeks, ensuring that the subject maintains a platelet count above a predetermined threshold during treatment.
Career Highlights
Klencke is currently associated with GlaxoSmithKline LLC, where she continues to innovate in the field of medical treatments. Her work has garnered attention for its potential to change the standard of care for patients with myelofibrosis.
Collaborations
Throughout her career, Klencke has collaborated with notable colleagues, including Gregg David Smith and Rafe Michael Joseph Donahue. These partnerships have contributed to the advancement of her research and the development of her patents.
Conclusion
Barbara Jane Klencke is a pioneering inventor whose work in myelofibrosis treatment is making a significant impact in the medical field. Her innovative approaches and collaborations highlight her commitment to improving patient outcomes.